Shorts:

• Pfizer will acquire all outstanding shares of Trillium for $18.50/share in cash making a total equity value of $2.26B with 203.8% premium on the stock's last closing price
• The acquisition will bolster Pfizer’s R&D capabilities & accelerates clinical development of Trillium’s SIRPα fusion proteins i.e.- TTI-622 & TTI-621 that are currently in P-Ib/II trial for hematological malignancies
• In clinical studies- TTI-622 & TTI-621 demonstrated the activity as monothx. in r/r lymphoid malignancies- including DLBCL- PTCL- FL- & other lymphoid malignancies. Additionally- Trillium's biologics treatments will enhance patients innate immune systems to detect & destroy cancer cells

  | Ref: Businesswire | Image: Trillium